Health Care [ 7/12 ] | Pharmaceuticals [ 40/74 ]
NASDAQ | Common Stock
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.
The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.
CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of TexasM. D.
Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 24 | -0.25 Increased by +90.64% | -0.10 Decreased by -152.70% |
| Aug 14, 24 | -6.72 Decreased by -547.88% | - |
| May 15, 24 | -0.41 Increased by +84.27% | - |
| Mar 14, 24 | -47.70 Decreased by -1.15 K% | - |
| Nov 13, 23 | -2.70 Increased by 0.00% | -2.40 Decreased by -12.50% |
| Aug 14, 23 | -1.04 Increased by +61.59% | - |
| May 15, 23 | -2.59 Decreased by -23.19% | - |
| Mar 31, 23 | -3.82 Decreased by -27.37% | -2.40 Decreased by -59.21% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -5.61 M Decreased by -23.95% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -2.53 M Increased by +37.07% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 6.36 K Increased by +N/A% | -3.54 M Increased by +28.28% | Decreased by -55.72 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -5.38 M Increased by +2.39% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -4.52 M Decreased by -32.24% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -4.02 M Decreased by -12.72% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -4.94 M Decreased by -77.36% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -5.51 M Decreased by -97.01% | Decreased by N/A% Decreased by N/A% |